AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 58(4), 1998, pp. 436-443
Copyright © 1998 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopez-Velez, R
Right arrow Articles by Alvar, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez-Velez, R
Right arrow Articles by Alvar, J
Related Collections
Right arrow AIDS
Right arrow Leishmaniasis
American Journal of Tropical Medicine and Hygiene, Vol 58, Issue 4, 436-443
Copyright © 1998 by American Society of Tropical Medicine and Hygiene

Research Articles


Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain

R Lopez-Velez, JA Perez-Molina, A Guerrero, F Baquero, J Villarrubia, L Escribano, C Bellas, F Perez-Corral, and J Alvar

From 1987 to 1995, a retrospective case study was conducted at the Ramon y Cajal Hospital in Madrid, Spain, a public teaching hospital with 1,100 beds, to determine the clinicoepidemiologic characteristics, survival, and prognostic factors of patients with visceral leishmaniasis (VL) and human immunodeficiency virus (HIV) infection. The prevalence of VL in HIV+ patients compared with HIV- patients was studied. Epidemiologic, clinical, and parasitologic characteristics, as well as the effects of treatment, prognosis, and survival in 54 HIV+ patients (90 episodes) with VL were defined. Comparative survival studies among patients with and without acquired immunodeficiency syndrome (AIDS)-defining criteria and multivariate analysis of survival risk factors were performed. The prevalence of VL in patients with AIDS was much higher than in immunocompetent individuals. In spite of a good initial response to treatment for VL, 60.6% of the patients had relapsed by the end of one year. Mortality from the first episode was 18.5%, and 24% died in the first month after diagnosis of any VL episode. The mean survival of the 29 patients who died was 10.27 months. Survival in patients with and without AIDS at the time of the first episode of VL was compared at 30 months: 53.7% versus 20.5% (P = 0.00149). We found no significant difference (P = 0.24) in the survival of HIV+ patients who had died of VL without AIDS at the time of the first episode of VL compared with those of a control group of 413 dead patients with AIDS without VL. A diagnosis of AIDS at the time of the first episode of VL and thrombocytopenia were the only risk factors found related to survival. We conclude that in AIDS patients, VL is a recurrent disease that is highly prevalent and whose clinical course is modified by HIV.


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
J. Alvar, P. Aparicio, A. Aseffa, M. Den Boer, C. Canavate, J.-P. Dedet, L. Gradoni, R. Ter Horst, R. Lopez-Velez, and J. Moreno
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Clin. Microbiol. Rev., April 1, 2008; 21(2): 334 - 359.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
P. Mathur, J. C. Samantaray, M. Vajpayee, and P. Samanta
Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics.
J. Med. Microbiol., July 1, 2006; 55(Pt 7): 919 - 922.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
C. Zhao, S. Thibault, N. Messier, M. Ouellette, B. Papadopoulou, and M. J. Tremblay
In primary human monocyte-derived macrophages exposed to Human immunodeficiency virus type 1, does the increased intracellular growth of Leishmania infantum rely on its enhanced uptake?
J. Gen. Virol., May 1, 2006; 87(Pt 5): 1295 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
C. RIERA, R. FISA, E. RIBERA, J. CARRIO, V. FALCO, M. GALLEGO, L. MONER, I. MOLINA, and M. PORTUS
VALUE OF CULTURE AND NESTED POLYMERASE CHAIN REACTION OF BLOOD IN THE PREDICTION OF RELAPSES IN PATIENTS CO-INFECTED WITH LEISHMANIA AND HUMAN IMMUNODEFICIENCY VIRUS
Am J Trop Med Hyg, December 1, 2005; 73(6): 1012 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Lopez-Velez, S. Videla, M. Marquez, V. Boix, M. E. Jimenez-Mejias, M. Gorgolas, J. R. Arribas, A. Salas, F. Laguna, M. Sust, et al.
Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients
J. Antimicrob. Chemother., March 1, 2004; 53(3): 540 - 543.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F. Laguna, S. Videla, M. E. Jimenez-Mejias, G. Sirera, J. Torre-Cisneros, E. Ribera, D. Prados, B. Clotet, M. Sust, R. Lopez-Velez, et al.
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study
J. Antimicrob. Chemother., September 1, 2003; 52(3): 464 - 468.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
L. J Roberts, E. Handman, and S. J Foote
Science, medicine, and the future: Leishmaniasis
BMJ, September 30, 2000; 321(7264): 801 - 804.
[Full Text]

Home page
 JWatch Infect. DiseasesHome page
Leishmaniasis and AIDS: Deadly Duo
Journal Watch Infectious Diseases, June 1, 1998; 1998(601): 16 - 16.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Tropical Medicine and Hygiene.